Strategy or setback?Asleykang may "withdraw from" $ 4 billion in new crown vaccine business

On Tuesday (August 23), Astraon released a signal to "exit" the new crown vaccine business.

In an interview with Reuters, Pascal Soriot, CEO of Astraikon, said: In the long run, the company may not continue the vaccine business. Regarding whether Astraon will expand other infectious diseases and vaccine business, Suboko said the company is conducting relevant evaluations.

In 2021, the revenue of Vaxzevria, the new crown vaccine of Astraikon, was US $ 3.917 billion, accounting for 10%of the total revenue. It was the second largest selling product in last year. Why did Astrakang want to give up?

The new crown vaccine "racing", Astraco may leave the game halfway?

In the early days of the epidemic, Astrick's response to the "new crown competition" was not slow.

As early as February 2020, Astrakang announced the cooperation with the University of Oxford University to develop the COVID-19 vaccine and was supported by the US official organization of over 1 billion U.S. dollars. Thanks to the years of research on the SARS vaccine, Astraon's progress is far ahead of competitors.

At the end of 2020, the Astrakang New Town Vaccine was urgently authorized in the UK, and the products of Pfizer/Biontech and Moderna had been listed in the United States.

Since then, in March 2021, the new crown vaccine in Astraco was challenged -some people have suspended vaccination after vaccination, and many countries around the world have announced suspension of vaccination. Until now, the vaccine has not been approved in the United States.

In any case, as a new product that was just one year, its revenue was nearly $ 4 billion, and the new crown vaccine of Astraikon still showed good potential.

However, this achievement can't stand the comparison.

In 2021, Pfizer's new crown vaccine COMIRNATY revenue reached 36.781 billion US dollars, and he pressed Aberville Merrobe to become a new generation of "medicine king", accounting for 45%of Pfizer's total revenue. Pfizer's partner Biontech revenue was US $ 22.44 billion, while Moderna revenue was 18.47 billion US dollars.

It can be seen that in terms of performance alone, the new crown vaccine of the Astraikon was not only nearly ten times behind Pfizer, but also was crushed by the two "post -rising shows". On the new crown vaccine, MRNA manufacturers locked the victory!

On the other hand, the continuous mutation of the new crown virus means that the "iteration" of the new crown vaccine must continue. In other words, the new crown vaccine competition is a "long -termism" without an end.

This month, Pfizer/BIONTECH and Moderna have submitted an authorization application to the US FDA to seek the approval of the Omikon BA.4 and BA.5 Asian variants. No follow -up means backward!

At the same time, more and more signs tell us that the dividend period of the new crown vaccine may enter the downward phase.

In Q2 this year, Biontech revenue was 3.2 billion euros (US $ 3.3 billion), a year-on-year-40%, and the former stars were also weak.

In the face of reality, the problem of Astraikon may be: in the face of a "cash dairy cow" that has doubts and challenges in the future, it is a continuous "feeding" of funds, turning it into a sustainable business, or choosing to let go -set up Subsidies, or are it completely sold?

This is indeed a major strategic issue. Persistence or abandonment is obviously needed to consider.

Continue to add long boards and continue to "buy and buy"?

The new crown vaccine business is to be determined in the future, so what are the plans of Astraon in the next step?

In an interview with Reuters, Suboko said that Astraikon was also looking for "external opportunities" to consider reinforcing acquisitions in the field of tumors and cardiovascular.

Astraon's annual revenue in 2021 was US $ 37.417 billion, a year -on -year+41%. There are 6 segmented businesses in total:

Tumor: revenue of US $ 13.048 billion, accounting for 35%, Astraon's largest business.

Cardiovascular, kidney, metabolism (CVRM): revenue of US $ 8.02 billion, accounting for 21%.

Breathing & Immunity (R & I): revenue of US $ 6.034 billion, accounting for 16%.

Rare disease: revenue of US $ 30.70 billion, accounting for 8%.

Other drugs: revenue of $ 2.367 billion, accounting for 6%.

COVID-19: revenue of US $ 4.002 billion, accounting for 11%.

It can be seen that oncology and cardiovascular are Astraik's strong business. The direction of mergers and acquisitions revealed by Suboko is undoubtedly a "plus long board", which further focuses on the choice of core competitiveness!

Astraikon's recent acquisitions are rare. The most well -known is the acquisition of Alexion's $ 39 billion in July 2021, which directly increased its head status in the global rare disease field.

In July of this year, Astrikon aimed at the field of tumor-announced that he plans to acquire biotechnology company Teneotwo, and will get a bilateral molecular therapy TNB-486, which is in the first clinical trial of Phase 1, with a total amount of up to 1.27 billion Dollar.

*TNB-486 is a T cell connector therapy that can also target the CD19 antigen on the surface of the B cells and the CD3 receptor on the T cell surface. Astraon is looking forward to further accelerating the development of this innovative therapy in B -cell malignant blood cancer, including large B -cell lymphoma and filtering lymphoma.

With the competition of global pharmaceutical companies entering the next stage, what choice will Astraikon make to challenge the leading "industry leaders"?Wait and see!Reference article:

Astrazeneca Reportedly Seeking Bolt-On Opportunities, Could

· END ·

- END -